Skip to main content

CITN-07 A Phase II, Open-label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand

Clinical Trial Grant
Duke Scholars

Administered By

Medicine, Medical Oncology

Awarded By

Fred Hutchinson Cancer Research Center

Start Date

September 1, 2014

End Date

December 31, 2018
 

Administered By

Medicine, Medical Oncology

Awarded By

Fred Hutchinson Cancer Research Center

Start Date

September 1, 2014

End Date

December 31, 2018